Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved tags : Biotech-bay save search
Tenon(R) Medical Announces Positive Fusion Results in First Patients Reaching 12-Month Follow Up in an IRB Approved, Multi-Centered, Post-Market Study Utilizing the Catamaran(R) SI Joint Fusion System
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
TNON | $0.7101 5.89% 7.3K
|
|
| O: 2.54%
H: 1.98%
C: -5.45%
first positive system medical results study
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB®
Published: 2024-03-18 (Crawled : 14:00) - biospace.com/
SCLX | $0.8407 -13.92% -16.18% 1.7M
|
|
| O: -0.73%
H: 3.31%
C: 0.74%
elyxyb drug patent company health approval review canada submission
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: 1.49%
H: 2.98%
C: -0.43%
fda pruritus approval treatment livmarli
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
SGMO | News | $0.4911 -5.72% -6.07% 1.2M
|
Health Technology
|
| O: 8.46%
H: 35.96%
C: 29.21%
st-920 fda disease approval prime ema therapeutics potential
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
Published: 2024-01-30 (Crawled : 15:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.34%
H: 0.13%
C: -0.23%
yescarta fda t-cell change approval therapy
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
Published: 2023-09-05 (Crawled : 18:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.6M
|
Health Services
|
| O: 0.0%
H: 7.57%
C: 0.86%
guardant360 lung japan diagnostic health her2 approval cancer cell treatment companion
U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
Published: 2023-08-29 (Crawled : 07:00) - biospace.com/
BMY | $48.86 -0.27% 0.0% 16M
|
Health Technology
|
| O: 0.55%
H: 2.31%
C: 1.4%
reblozyl fda anemia treatment
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
Published: 2023-04-17 (Crawled : 23:00) - biospace.com/
LJPC | $6.22 0.0%
|
Health Technology
| Email alert
Add to watchlist
INVA | $15.15 -0.13% -0.13% 420K
|
Health Technology
| Email alert
Add to watchlist
fda approval
Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis
Published: 2023-04-05 (Crawled : 15:20) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: -0.2%
H: 1.97%
C: -0.76%
approval livmarli
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
Published: 2023-03-10 (Crawled : 17:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.6M
|
Health Services
|
| O: -0.59%
H: 0.3%
C: -6.61%
blood drug test health application approval food
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 3.45%
H: 10.33%
C: 2.67%
vitargus biopharma approval tga study
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution
Published: 2023-01-09 (Crawled : 20:00) - biospace.com/
CALA | $0.029 150.0% 580
|
Health Technology
|
| O: -79.56%
H: 6.76%
C: -10.8%
approval
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
Published: 2023-01-05 (Crawled : 15:00) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 106.45%
H: 46.09%
C: -16.41%
abv-1519 treatment fda biopharma lung cancer study submission
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval
Published: 2022-11-17 (Crawled : 14:00) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 1.28%
H: 0.0%
C: -2.53%
vitargus fda biopharma approval update study
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
Published: 2022-11-02 (Crawled : 12:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -1.46%
H: 2.33%
C: -0.38%
vemlidy treatment hepatitis drug virus food infection chronic hepatitis b
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Published: 2022-10-14 (Crawled : 15:20) - biospace.com/
ATRA | $0.7101 -1.18% -1.2% 700K
|
Health Technology
|
| O: 3.76%
H: 0.47%
C: -9.9%
treatment disease chmp approval
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in ChinaMupadolimab clinical trial in China will be conducted by Angel Pharmaceuticals
Published: 2022-09-26 (Crawled : 22:00) - biospace.com/
CRVS | $1.58 3.27% 3.16% 91K
|
Health Technology
|
| O: 0.26%
H: 2.99%
C: -2.36%
cd73 pharmaceuticals trial approval china
Silk Road Medical Announces First Patient Enrolled in ROADSTER 3 Post Approval Study Evaluating TCAR® System in the Treatment of Standard Surgical Risk Patients
Published: 2022-09-07 (Crawled : 22:00) - biospace.com/
SILK | $17.58 -0.51% -0.51% 610K
|
Health Technology
|
| O: -0.1%
H: 7.08%
C: 6.79%
tcar treatment risk system approval study
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-08-24 (Crawled : 22:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -4.66%
H: 0.0%
C: -1.69%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -0.75%
H: 3.45%
C: 2.49%
tecvayli treatment approval
Gravity Branding names Novartis’ Vijoice® (alpelisib)Expert naming process valued in fast-tracked approval as drug clears FDA regulatory hurdles
Published: 2022-08-08 (Crawled : 22:00) - biospace.com/
SRE | $72.04 0.73% 0.0% 2.3M
|
Utilities
|
| O: 0.7%
H: 0.68%
C: 0.03%
vijoice fda drug approval
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.